{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T03:52:49Z","timestamp":1778212369908,"version":"3.51.4"},"reference-count":57,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","europeanneuropsychopharmacology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.euroneuro.2018.06.005","type":"journal-article","created":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T17:09:46Z","timestamp":1531847386000},"page":"1024-1034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Dose reduction of high-dose first-generation antipsychotics or switch to ziprasidone in long-stay patients with schizophrenia: A 1-year double-blind randomized clinical trial"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7273-0027","authenticated-orcid":false,"given":"Jan P.A.M.","family":"Bogers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter F.J.","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theo G.","family":"Broekman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Moleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lieuwe","family":"de Haan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2018.06.005_bib0001","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.4088\/JCP.09m05785yel","article-title":"An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis","volume":"72","author":"Agid","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0002","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2000"},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0003","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1176\/appi.ajp.2013.12050674","article-title":"Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study","volume":"170","author":"Andreasen","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0004","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.biopsych.2009.08.040","article-title":"Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs","volume":"67","author":"Andreasen","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0006","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/JCP.0000000000000478","article-title":"Clozapine underutilization in the treatment of schizophrenia: how can clozapine prescription rates be improved?","volume":"36","author":"Bogers","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0007","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.4088\/JCP.14m09321","article-title":"Switching from 2 antipsychotics to 1 antipsychotic in schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"77","author":"Borlido","year":"2016","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.euroneuro.2018.06.005_bib0008","first-page":"4","article-title":"Strategies for dosing and switching antipsychotics for optimal clinical management","volume":"69","author":"Buckley","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0009","first-page":"1","article-title":"New standards for negative symptom assessment","volume":"42","author":"Carpenter","year":"2016","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0010","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1176\/ajp.156.3.412","article-title":"Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks","volume":"156","author":"Carpenter","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0011","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2165\/00003088-198611010-00003","article-title":"Plasma level monitoring of antipsychotic drugs clinical utility","volume":"11","author":"Dahl","year":"1986","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0013","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1176\/appi.ajp.157.6.1019","article-title":"Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone","volume":"157","author":"De Haan","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0014","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1177\/070674370404900503","article-title":"Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications","volume":"49","author":"De Haan","year":"2004","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0015","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1176\/appi.ajp.160.2.303","article-title":"Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study","volume":"160","author":"De Haan","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0016","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1176\/ajp.2006.163.12.2090","article-title":"Effectiveness of switching antipsychotic medications","volume":"163","author":"Essock","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0017","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1176\/appi.ajp.2011.10060908","article-title":"Effectiveness of switching from antipsychotic polypharmacy to monotherapy","volume":"168","author":"Essock","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0018","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/schbul\/sbw020","article-title":"Diagnostic stability of ICD\/DSM first episode psychosis diagnosis: meta-analysis","volume":"42","author":"Fusar-Poli","year":"2016","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0019","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/wps.20446","article-title":"Improving outcomes of first-episode psychosis: an overview","volume":"16","author":"Fusar-Poli","year":"2017","journal-title":"World Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0020","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/schbul\/sbu170","article-title":"Treatment of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials","volume":"41","author":"Fusar-Poli","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0021","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1517\/14740338.2012.683523","article-title":"Safety and tolerability of antipsychotic polypharmacy","volume":"11","author":"Gallego","year":"2012","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0022","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","article-title":"International consensus study of antipsychotic dosing","volume":"167","author":"Gardner","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0023","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/bmj.321.7273.1371","article-title":"Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis","volume":"321","author":"Geddes","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0024","series-title":"ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76\u2013338","first-page":"217","author":"Guy","year":"1976"},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0025","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/schbul\/14.1.97","article-title":"REHAB, a multipurpose assessment instrument for long stay psychiatric patients","volume":"14","author":"Hall","year":"1988","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0026","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0027","doi-asserted-by":"crossref","first-page":"516","DOI":"10.4088\/JCP.v63n0609","article-title":"A 28 week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia","volume":"63","author":"Hirsch","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0028","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/archpsyc.1988.01800330021002","article-title":"Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study","volume":"45","author":"Hogarty","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0029","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0031","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1176\/ajp.151.12.1753","article-title":"A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients","volume":"151","author":"Inderbitzin","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0032","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1192\/bjp.151.5.634","article-title":"Double blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia","volume":"151","author":"Johnson","year":"1987","journal-title":"Br. J. Psychiatry"},{"issue":"suppl 1","key":"10.1016\/j.euroneuro.2018.06.005_bib0033","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1093\/schbul\/sby014.127","article-title":"Optimising the treatment and management of first-episode schizophrenia: the optimise clinical trial","volume":"44","author":"Kahn","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0034","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.yic.0000182114.65134.81","article-title":"Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia","volume":"21","author":"Kane","year":"2006","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0035","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.psychres.2012.08.019","article-title":"Subscale structure for the Positive and Negative Syndrome Scale (PANSS): a proposed solution focused on clinical validity","volume":"205","author":"Kelley","year":"2013","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0036","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1176\/appi.ps.54.11.1491","article-title":"Integrating treatment with rehabilitation for persons with major mental illnesses","volume":"54","author":"Kopelowicz","year":"2003","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0037","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/schbul\/sbp130","article-title":"The schizophrenia patient outcomes research team (PORT): updated treatment recommendations 2009","volume":"36","author":"Kreyenbuhl","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0038","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0039","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0040","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht","year":"2009","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0041","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jpsychires.2013.01.024","article-title":"Two subdomains of negative symptoms in psychotic disorders: established and confirmed in two large cohorts","volume":"47","author":"Liemburg","year":"2013","journal-title":"J. Psychiatr. Res."},{"issue":"suppl 334","key":"10.1016\/j.euroneuro.2018.06.005_bib0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale","volume":"76","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0043","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cpr.2010.09.002","article-title":"Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research","volume":"31","author":"Messinger","year":"2011","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0044","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/nrd.2016.28","article-title":"Altering the course of schizophrenia: progress and perspectives","volume":"5","author":"Millan","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0045","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Mongomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0046","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/01.yic.0000182121.59296.70","article-title":"Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week double-blind study","volume":"21","author":"Oli\u00e9","year":"2006","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0047","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of sudden cardiac death","volume":"360","author":"Ray","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0048","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jamapsychiatry.2015.2955","article-title":"Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis","volume":"73","author":"Samara","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0049","doi-asserted-by":"crossref","first-page":"352","DOI":"10.5498\/wjp.v5.i4.352","article-title":"Conceptualization and treatment of negative symptoms in schizophrenia","volume":"5","author":"Sarkar","year":"2015","journal-title":"World J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0050","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3371\/CSRP.4.1.5","article-title":"Dopamine D2 receptors as treatment targets in schizophrenia","volume":"3","author":"Seeman","year":"2010","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0051","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0014-2999(01)01188-8","article-title":"Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile","volume":"425","author":"Schmidt","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0052","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00213-013-3012-1","article-title":"Dopamine D2\/3 occupancy of ziprasidone across a day: a within-subject PET study","volume":"228","author":"Suzuki","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0053","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/00004850-200311000-00003","article-title":"Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia","volume":"18","author":"Suzuki","year":"2003","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0054","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.4088\/JCP.13m08841","article-title":"Dose reduction of risperidone and olanzapine and estimated dopamine D-receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study","volume":"75","author":"Takeuchi","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0056","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00131746-200505000-00003","article-title":"Psychiatrists and psychiatric rehabilitation","volume":"11","author":"Torrey","year":"2006","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0057","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0920-9964(01)00374-7","article-title":"Neuroleptic dose reduction in stable chronic schizophrenia","volume":"59","author":"Tsuruta","year":"2003","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0058","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4088\/JCP.v64n0514","article-title":"Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia","volume":"64","author":"Weiden","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0059","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1055\/s-2007-1014514","article-title":"The development of an observer-scale for measuring social dysfunction and aggression","volume":"23","author":"Wistedt","year":"1990","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0060","author":"Wu"},{"key":"10.1016\/j.euroneuro.2018.06.005_bib0061","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3109\/09540261.2010.482558","article-title":"Are we using excessive neuroleptics? An argument for systematic neuroleptic dose reduction in stable patients with schizophrenia with specific reference to clozapine","volume":"22","author":"Yamin","year":"2010","journal-title":"Int. Rev. Psychiatry"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X18301652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X18301652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T19:46:06Z","timestamp":1661629566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X18301652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":57,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0924977X18301652"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2018.06.005","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose reduction of high-dose first-generation antipsychotics or switch to ziprasidone in long-stay patients with schizophrenia: A 1-year double-blind randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2018.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}